|
Intangible Assets (Details Textual) (USD $)
|
3 Months Ended | 3 Months Ended | |||||
|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
|
Mar. 31, 2013
|
Mar. 31, 2014
Subscriber relationships [Member]
|
Mar. 31, 2014
Licensing agreements [Member]
|
Jul. 31, 2008
Trademarks [Member]
|
Mar. 31, 2014
Agero, Inc. [Member]
Original equipment manufacturer relationships (OEM) [Member]
|
Mar. 31, 2014
Agero, Inc. [Member]
Proprietary software [Member]
|
|
| Intangible Assets (Textual) [Abstract] | |||||||
| Purchase price related to merger | $ 250,000,000 | ||||||
| Impairment loss related to indefinite-lived intangibles | 0 | 0 | |||||
| Intangible assets (Additional Textual) [Abstract] | |||||||
| Weighted average useful lives (in years) | 9 years | 9 years 1 month 6 days | 15 years | 10 years | |||
| Amortization expense | $ 14,084,000 | $ 12,591,000 | |||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|